Search results for "infarct"

showing 10 items of 1223 documents

Risk score for early risk prediction by cardiac magnetic resonance after acute myocardial infarction.

2022

BACKGROUND: Cardiac magnetic resonance (CMR) performed early after ST-segment elevation myocardial infarction (STEMI) can improve major adverse cardiac event (MACE) risk prediction. We aimed to create a simple clinical-CMR risk score for early MACE risk stratification in STEMI patients.; METHODS: We performed a multicenter prospective registry of reperfused STEMI patients (n=1118) in whom early (1-week) CMR-derived left ventricular ejection fraction (LVEF), infarct size and microvascular obstruction (MVO) were quantified. MACE was defined as a combined clinical endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (NF-MI) or re-admission for acute decompensated heart failur…

Malemedicine.medical_specialtyMagnetic Resonance SpectroscopyAcute decompensated heart failureMyocardial InfarctionMagnetic Resonance Imaging CineVentricular Function LeftPercutaneous Coronary InterventionRisk FactorsInternal medicineClinical endpointMedicineHumansMyocardial infarctioncardiovascular diseasesAgedFramingham Risk ScoreEjection fractionbusiness.industryMean ageStroke VolumeMiddle Agedmedicine.diseasePrognosiscardiovascular systemCardiologyST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonanceMace
researchProduct

Prediction of long-term major events soon after a first ST-segment elevation myocardial infarction by cardiovascular magnetic resonance.

2016

Cardiovascular magnetic resonance (CMR) predicts combined clinical events in post-ST-segment elevation myocardial infarction (STEMI) patients. However, its contribution to predicting long-term major events (ME: cardiac death and non-fatal myocardial infarction [MI]) is unknown. We aimed to assess whether CMR predicts long-term MEs when performed soon after STEMI.We prospectively recruited 546 STEMI patients between 2004 and 2012. The Left ventricular (LV) ejection fraction (LVEF,%), infarct size (IS), edema, hemorrhage, microvascular obstruction, and myocardial salvage were quantified by CMR at pre-discharge. During a mean follow-up of 840 days, 57 ME events (10%; 23 cardiac deaths, 34 non-…

Malemedicine.medical_specialtyMagnetic Resonance SpectroscopyMyocardial InfarctionHemorrhage030204 cardiovascular system & hematologyTime03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineEdemaInternal medicinemedicineST segmentEdemaHumansRadiology Nuclear Medicine and imagingcardiovascular diseases030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesEjection fractionmedicine.diagnostic_testClinical eventsbusiness.industryMyocardiumReproducibility of ResultsMagnetic resonance imagingGeneral MedicineMiddle AgedInfarct sizemedicine.diseaseMicrovesselscardiovascular systemCardiologyFemalemedicine.symptombusinessCardiac deathsFollow-Up StudiesEuropean journal of radiology
researchProduct

EpCAM and microvascular obstruction in patients with STEMI: a cardiac magnetic resonance study

2020

Abstract Introduction and objectives Microvascular obstruction (MVO) is negatively associated with cardiac structure and worse prognosis after ST-segment elevation myocardial infarction (STEMI). Epithelial cell adhesion molecule (EpCAM), involved in epithelium adhesion, is an understudied area in the MVO setting. We aimed to determine whether EpCAM is associated with the appearance of cardiac magnetic resonance (CMR)-derived MVO and long-term systolic function in reperfused STEMI. Methods We prospectively included 106 patients with a first STEMI treated with percutaneous coronary intervention, quantifying serum levels of EpCAM 24 hours postreperfusion. All patients underwent CMR imaging 1 w…

Malemedicine.medical_specialtyMagnetic Resonance Spectroscopymedicine.medical_treatmentMagnetic Resonance Imaging Cine030204 cardiovascular system & hematologyVentricular Function Left03 medical and health scienceschemistry.chemical_compoundPercutaneous Coronary Intervention0302 clinical medicineInternal medicinemedicineHumansIn patientcardiovascular diseasesMyocardial infarctionVentricular remodelingEnd-systolic volumeAgedEjection fractionbusiness.industryMicrocirculationPercutaneous coronary interventionStroke VolumeEpithelial cell adhesion moleculeGeneral MedicineMiddle AgedEpithelial Cell Adhesion Moleculemedicine.diseaseMagnetic Resonance ImagingchemistryCardiologyST Elevation Myocardial InfarctionFemalebusinessCardiac magnetic resonancehuman activitiesRevista Española de Cardiología (English Edition)
researchProduct

Protective effect of N-acetylcysteine on ischaemia-induced myocardial damage in canine heart.

1991

The glutathione redox pathway is an important antioxidant system in the myocardium. N-Acetylcysteine is a low molecular weight glutathione precursor that has been used clinically to replenish glutathione stores. The present study was aimed at evaluating the protective effect of N-acetylcysteine on myocardial damage resulting from permanent coronary occlusion (without reperfusion) in anaesthetized dogs. N-Acetylcysteine (150 mg kg−1 i.v.) administered 2 min before occlusion rerduced infarct size in dogs subjected to 24 h ischemia. The infarct size as a percentage of the area at risk was 86.8 ± 3.6% (n = 11) in control (salinetreated) dogs and 68.2 ± 2.4% (n = 7; P < 0.05 vs control) in N-ace…

Malemedicine.medical_specialtyMean arterial pressureTime FactorsIschemiaMyocardial InfarctionHemodynamicsCoronary DiseaseAcetylcysteinechemistry.chemical_compoundDogsInternal medicineCoronary CirculationmedicineAnimalsMyocardial infarctionPharmacologybusiness.industryGeneral MedicineGlutathionemedicine.diseaseMalondialdehydeGlutathioneAcetylcysteineDisease Models AnimalchemistryCoronary occlusionAnesthesiaCardiologyFemalebusinessmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Administration of transforming growth factor-α reduces infarct volume after transient focal cerebral ischemia in the rat

2001

Growth factors promote cell growth and survival and protect the brain from developing injury after ischemia. In this article, the authors examined whether transforming growth factor-α (TGF-α was protective in transient focal ischemia and whether alteration of cerebral circulation was involved. Rats received intraventricular TGF-α (50 ng, either split into 2 doses given 30 minutes before and 30 minutes after middle cerebral artery occlusion (MCAO), or 1 dose given 30 minutes after MCAO) or vehicle. Rats were subjected to 1-hour intraluminal MCAO and cerebral blood flow was recorded continuously by laser-Doppler flowmetry. Infarct volume was measured 1 and 4 days later. The effects of TGF-α o…

Malemedicine.medical_specialtyMicrovascular perfusionCerebral arteriesIschemiaRabbitIn Vitro Techniques030218 nuclear medicine & medical imagingMicrocirculationBrain IschemiaRats Sprague-Dawley03 medical and health sciencesCerebral circulation0302 clinical medicineInternal medicinemedicineAnimalscardiovascular diseasesMiddle cerebral artery occlusionCerebral infarctionbusiness.industryMicrocirculationInfarction Middle Cerebral ArteryTransforming Growth Factor alphamedicine.diseaseRatsCarotid ArteriesNeuroprotective AgentsNeurologyCerebral blood flowVasoconstrictionAnesthesiaBasilar ArteryCerebrovascular CirculationCardiologyRatNeurology (clinical)Rabbitsmedicine.symptomCardiology and Cardiovascular MedicinebusinessGrowth factors030217 neurology & neurosurgeryVasoconstrictionTransforming growth factor
researchProduct

Diabetic 3rd nerve palsy: evidence for a mesencephalic lesion.

1990

Eleven consecutive adult chronic diabetic patients presented with an isolated 3rd nerve palsy (8 with pupillary sparing) of which 10 had abnormal ipsilateral or bilateral masseter reflexes (MassR). Three patients had an MRI lesion in the ipsilateral oculomotor fasciculus and 3 had subsequent mild brainstem signs. An additional 13 patients with Weber's syndrome had similar ipsilateral or bilateral MassR abnormalities, while 7 patients with 3rd nerve palsies on a known extra-axial basis had none. The findings suggest that an isolated diabetic 3rd nerve palsy, with or without pupillary sparing, is much more likely on the basis of a focal mesencephalic infarct than a peripheral nerve lesion.

Malemedicine.medical_specialtyMidbrainMasseter muscleLesionDiabetic NeuropathiesOculomotor NerveMesencephalonDiabetes mellitusFasciculusParalysisOculomotor Nerve DiseasesMedicineHumansAgedAged 80 and overbiologybusiness.industryCerebral InfarctionMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryAnesthesiaReflexFemaleNeurology (clinical)Brainstemmedicine.symptombusinessNeurology
researchProduct

Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.

2010

408 Positional cerebral ischemia (PCI) is an extremely rare condition in which dramatic central nervous system deficits are triggered by standing in patients with severe stenosis or occlusion of the major brain-supplying blood vessels [1] . Because PCI is generally associated with orthostatic hypotension [2, 3] , a hemodynamic mechanism has been proposed [4] . However, PCI has been reported even in patients without orthostatic hypotension [1] . The treatment is medical, but surgery can be considered in refractory cases (endarterectomy for carotid artery stenosis or either highor low-flow extra-intracranial bypass – for carotid occlusion) [3] . We report a case of PCI associated with middle …

Malemedicine.medical_specialtyMiddle Cerebral ArterySettore MED/09 - Medicina InternaTiclopidinePostureIschemiaHemodynamicsOrthostatic vital signsmedicine.arteryInternal medicineParietal LobeOcclusionmedicineHumansThrombophiliacardiovascular diseasesCerebral perfusion pressureTomography Emission-Computed Single-Photonpositional ischemia Extracranial by-passAspirinCerebral Revascularizationbusiness.industryInfarction Middle Cerebral ArteryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingClopidogrelTemporal ArteriesParesisHemiparesisBlood pressureNeurologyIschemic Attack TransientAnesthesiaMiddle cerebral arteryCardiologyNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCerebrovascular diseases (Basel, Switzerland)
researchProduct

Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up

2014

Silent atrial fibrillation (AF), assessed by continuous ECG monitoring (CEM), has recently been shown to be common in acute myocardial infarction (AMI), and associated with higher hospital mortality. However, the long-term prognosis is still unknown. We aimed to assess 1-year prognosis in patients experiencing silent AF in AMI.All consecutive patients with AMI who were prospectively analysed by CEM during the first 48 h after admission and who survived at hospital discharge were included. Silent AF was defined as asymptomatic episodes lasting at least 30 s. Patients were followed up at 1 year for cardiovascular (CV) outcomes.Among the 737 patients analysed, 106 (14%) developed silent AF and…

Malemedicine.medical_specialtyMyocardial Infarction1 year follow upAsymptomaticElectrocardiographyInternal medicineAtrial FibrillationEpidemiologyHospital dischargeHumansMedicineIn patientcardiovascular diseasesMyocardial infarctionProspective cohort studyAgedAged 80 and overbusiness.industryAtrial fibrillationMiddle AgedPrognosismedicine.diseaseHospitalizationStrokeCardiologyFemalemedicine.symptomEpidemiologic MethodsCardiology and Cardiovascular MedicinebusinessHeart
researchProduct

Association between AT C573T polymorphism and cardiovascular risk factors in myocardial infarction.

2011

Abstract Background Polymorphisms in the AT1 gene have been associated with various parameters related to the pathogenesis of cardiovascular diseases and to myocardial infarction. This study analyzed the relationship between two polymorphisms of the angiotensin II AT-1 receptor gene (AT1_1166 and AT1_573) and the risk of ischemic heart disease by studying their association with several cardiovascular risk factors. Methods The sample population comprised 356 subjects: 174 patients who had survived myocardial infarction (61.01±8.15 years), and 182 age- and gender-matched controls (mean age of 60.25±9.43). The polymorphisms of the angiotensin II AT1-receptor gene (C573T and A1166C) were studie…

Malemedicine.medical_specialtyMyocardial InfarctionDiseaseGastroenterologyPolymorphism Single NucleotideRisk AssessmentReceptor Angiotensin Type 1Pathology and Forensic Medicinelaw.inventionPathogenesisGene FrequencylawRisk FactorsInternal medicineGenotypemedicineOdds RatioHumansGenetic Predisposition to DiseaseMyocardial infarctionPolymerase chain reactionAgedRetrospective StudiesAnalysis of VarianceAngiotensin II receptor type 1Chi-Square Distributionbusiness.industryGeneral MedicineAnthropometryMiddle Agedmedicine.diseaseAngiotensin IILogistic ModelsPhenotypeHaplotypesSpainCase-Control StudiesCardiologyFemaleCardiology and Cardiovascular MedicinebusinessCardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
researchProduct

Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.

2006

Aims C-reactive protein and fibrinogen have been extensively studied and shown to be predictive for a first cardiovascular event in healthy individuals. We evaluated the potential clinical use of C-reactive protein and fibrinogen in patients already suffering from coronary artery disease (CAD). Methods and results In a substudy of the prospective Athero Gene registry, we assessed in 1806 patients with documented CAD and stable angina pectoris, the risk of cardiovascular death and non-fatal myocardial infarction ( n =183) over a median follow-up of 3.5 (maximum 7.7) years according to baseline levels of C-reactive protein and fibrinogen. C-reactive protein and fibrinogen were associated with…

Malemedicine.medical_specialtyMyocardial InfarctionFibrinogenDisease-Free SurvivalAngina PectorisCoronary artery diseaseRisk FactorsInternal medicinemedicineHumansIn patientMyocardial infarctionRisk factorbiologybusiness.industryC-reactive proteinConfoundingCoronary StenosisFibrinogenMiddle Agedmedicine.diseasePrognosisC-Reactive ProteinCardiovascular DiseasesCirculatory systembiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugEuropean heart journal
researchProduct